Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients
OFF Time Was Reduced With Longer-Acting Levodopa Product
The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose.
You may also be interested in...
Amneal says it is taking initiatives to improve its generics margins by improving its manufacturing and supply chain, after its generics segment was sales drop by 11% in the first quarter. Amneal is aiming to deliver six to seven high-value products annually, while the company is also looking to launch three biosimilars in the next couple of years.
The FDA on 8 January finally gave its blessing to Impax Pharmaceuticals to market its Parkinson's disease drug Rytary, an extended-release oral capsule formulation of carbidopa-levodopa.
Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.